Business oriented EU human cell and tissue product legislation will adversely impact Member States' health care systems

Cell and Tissue Banking

Volumn 14, Issue 4, 2013, Pages 525-560

  Pirnay, Jean Paul ^a   Vanderkelen, Alain ^a   De Vos, Daniel ^a   Draye, Jean Pierre ^a   Rose, Thomas ^a   Ceulemans, Carl ^b   Ectors, Nadine ^c   Huys, Isabelle ^d   Jennes, Serge ^a   Verbeken, Gilbert ^a  

^a QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^b ROYAL MILITARY ACADEMY   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Advanced therapy medicinal product; Cell and tissue banking; European Union; Public health; Regulation; Tissue engineering

Indexed keywords

ARTICLE; CELL TRANSPLANTATION; COMMERCIAL PHENOMENA; DRUG INDUSTRY; ECONOMICS; ETHICS; EUROPEAN UNION; HEALTH CARE DELIVERY; HUMAN; LAW; LEGAL ASPECT; POLICY; TRANSPLANTATION;

CELL TRANSPLANTATION; COMMERCE; DELIVERY OF HEALTH CARE; DRUG INDUSTRY; EUROPEAN UNION; HUMANS; LEGISLATION AS TOPIC; POLICY; TRANSPLANTS;

EID: 84891349154     PISSN: 13899333     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10561-013-9397-6     Document Type: Article

References (99)

1. Apperley F (2012) Advanced therapies and therapeutic advance in Europe. Academic GMP - CONTRACT joint conference: the impact of EU legislation on therapeutic advance, Brussels, 11 October 2012
2. Barnes K (2006) Human tissue worth more than diamonds. DrugResearcher.com. http://www.asterand.com/asterand/investors/publishednews/ 2006/Asterand06072006.pdf. Accessed 2 Nov 2012
3. Baroso JM (2005) Communication to the Spring European Council - working together for growth and jobs - a new start for the Lisbon Strategy [SEC(2005) 192) - (SEC(2005) 193]. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri= CELEX:52005DC0024:EN:NOT. Accessed 2 Nov 2012
4. Beder S (2009) Neoliberalism and the global financial crisis. Soc Altern 8:17-21
5. Birger J (2006) Give me some skin. Fortune Magazine, 7 September. http://money.cnn.com/magazines/fortune/fortune-archive/2006/09/04/8384735/index. htm. Accessed 2 Nov 2012
6. Bock AK, Ibarreta D, Rodriguez-Cerezo E (2003) Human tissue engineered products - today's markets and future prospects (Report EUR 21 000 EN). European Commission Joint Research Centre (DG JRC) Institute for Prospective Technological Studies (IPTS). http://ec.europa.eu/health/files/advtherapies/ docs/memo-05-429-en.pdf. Accessed 2 Nov 2012
7. Bock AK, Rodriguez-Cerezo E, Hüsing B, Bührlen B, Nusser M (2005) Human tissue engineered products: potential socio-economic impacts of a new European regulatory framework for authorisation, supervision and vigilance (report EUR 21 838 EN). European Commission Joint Research Centre (DG JRC) Institute for Prospective Technological Studies (IPTS). http://ftp.jrc.es/ EURdoc/eur21838en.pdf. Accessed 2 Nov 2012
8. Bredin Prat (2012) Avis HMRA - Kératinocytes - 2012
9. Buckler RL (2012) Cell therapy industry overview: metrics & trends. 10th Annual National Blood Foundation Leadership Forum, Washington, 22-24 April. http://www.aabb.org/programs/nbf/lf/Documents/LF12Buckler1.pdf. Accessed 12 Nov 2012
10. Cavanaugh TA (2006) Double-effect reasoning: doing good and avoiding evil. Oxford University Press, Oxford
11. Chrisafis A (2011) French government 'to order women to remove defective breast implants'. The Guardian, 20 December. http://www.guardian.co.uk/world/ 2011/dec/20/french-remove-breast-implants-silicone. Accessed 2 Nov 2012
12. Collins S (2001) Tissue banks: is the federal government's oversight adequate? Hearing before the Committee on Governmental Affairs, U.S. Senate. Diane Publishing Company, Washington DC
13. Council of Europe (1997) Convention for the protection of human rights and dignity of the human being with regard to the application of biology and medicine: convention on human rights and biomedicine. http://conventions.coe. int/Treaty/en/Treaties/html/164.htm. Accessed 2 Nov 2012
14. Council of Europe (2009) Trafficking in organs, tissues and cells and trafficking in human beings for the purpose of the removal of organs. Joint Council of Europe/United Nation study. http://www.coe.int/t/dghl/monitoring/ trafficking/docs/news/OrganTrafficking-study.pdf. Accessed 2 Nov 2012
15. Cuende N, Rico L, Herrera C (2012) Concise review: bone marrow mononuclear cells for the treatment of ischemic syndromes: medicinal product or cell transplantation? Stem Cells Trans Med 1:403-408
16. Daley GQ (2012) The promise and perils of stem cell therapeutics. Cell Stem Cell 10:740-749
17. De Corte P, Verween G, Verbeken G, Rose T, Jennes S, De Coninck A, Roseeuw D, Vanderkelen A, Kets E, Haddow D, Pirnay JP (2012) Feeder layer- and animal product-free culture of neonatal foreskin keratinocytes: improved performance, usability, quality and safety. Cell Tissue Bank 13:175-189
18. Donawa M, Gray R (2012) The breast implant scandal and European medical device regulation. GMP Rev 11:2-4
19. EGE (1998) Opinion No 11 to the European Commission. Ethical aspects of human tissue banking. http://ec.europa.eu/bepa/european-group-ethics/docs/ avis11-en.pdf. Accessed 2 Nov 2012
20. EMA (2009) ChondroCelect. Characterized viable autologous cartilage cells expanded ex vivo expressing specific marker proteins. EPAR summary for the public (EMEA/414188/2009). http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Summary-for-the-public/human/000878/WC500026033.pdf. Accessed 2 Nov 2012
21. EMA (2012) Annexes of the annual report 2011 http://www.ema.europa.eu/ docs/en-GB/document-library/Annual-report/2012/06/WC500128161.pdf? bcsi-scan-b4a65a56ef99b716=0&bcsi-scan-filename=WC500128161.pdf. Accessed 2 Nov 2012
22. EMA/CAT (2010) Committee for advanced therapies work programme 2010-2015 (EMA/CAT235374/2010). http://www.ema.europa.eu/docs/en-GB/document-library/Work- programme/2010/11/WC500099029.pdf. Accessed 12 Nov 2012
23. EMA/CAT (2012a) Summaries of scientific recommendations on classification of advanced-therapy medicinal products. http://www.ema.europa.eu/ema/index.jsp? curl=pages/regulation/general/general-content-000301.jsp&mid= WC0b01ac05800862c0. Accessed 3 Nov 2012
24. EMA/CAT (2012b) CAT monthly report of application procedures, guidelines and related documents on advanced therapies (EMA/CAT/608504/2012). http://www.ema.europa.eu/docs/en-GB/document-library/Committee-meeting-report/ 2012/10/WC500134056.pdf. Accessed 2 Nov 2012
25. Etzkowitz H (2003) Research groups as 'quasi-firms': the invention of the entrepreneurial university. Res Policy 32:109-121
26. Eucomed (2004) Proposal for a Regulation of the European Parliament and of the Council on Advanced Therapies and amending Regulation (EC) No 726/2004. http://www.eucomed.org/uploads/Modules/Publications/HumanTissueProducts- EucomedProposal.pdf. Accessed 3 Nov 2012
27. Eucomed (2005) Position paper on the proposal for a community regulatory framework on advanced therapies of 04 May 2005. http://www.eucomed.org/uploads/ Modules/Publications/HumanTissueProducts-PositionPapers.pdf. Accessed 3 Nov 2012
28. Eucomed (2008) Advanced therapy medicinal products backgrounder. http://www.eucomed.org/uploads/Modules/Publications/ AdvancedTherapyMedicinalProducts.pdf. Accessed 3 Nov 2012
29. EurActiv (2002) Health Ministers discuss possible new Directive on human tissue and cell transplants. EurActiv.com. http://www.euractiv.com/cap/health- ministers-discuss-possible-new-directive-human-tissue-cell-transplants/ article-112726. Accessed 2 Nov 2012
30. EurActiv (2004a) Council clears the way for new legislation on human tissues and cells. Euractiv.com. http://www.euractiv.com/health/council-clears- way-new-legislation-human-tissues-cells/article-111803. Accessed 3 Nov 2012
31. EurActiv (2004b) In March 2000, the EU Heads of States and Governments agreed to make the EU "the most competitive and dynamic knowledge-driven economy by 2010. Although some progress was made on innovating Europe's economy, there is growing concern that the reform process is not going fast enough and that the ambitious targets will not be reached. EurActiv.com. http://www.euractiv.com/future-eu/lisbon-agenda/article-117510?display=normal. Accessed 2 Nov 2012
32. EuropaBio (2002) DG Sanco proposed directive regarding quality and safety of tissues and cells. Public hearing. European Parliament
33. European Union (1993) Council directive 93/42/EEC of 14 June 1993 concerning medical devices, as amended. http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=OJ:L:1993:169:0001:0043:EN:PDF. Accessed 3 Nov 2012
34. European Union (1997) Treaty of Amsterdam amending the Treaty on the European Union, the treaties establishing the European Communities and related act. http://eur-lex.europa.eu/en/treaties/dat/11997D/htm/11997D.html#0001010001. Accessed 3 Nov 2012
35. European Union (2000) Presidency conclusions. Lisbon. http://www.consilium.europa.eu/uedocs/cms-data/docs/pressdata/en/ec/00100-r1. en0.htm. Accessed 11 Nov 2012
36. European Union (2001a) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, as amended. http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do?uri=OJ:L:2001:311:0067:0128:EN:PDF. Accessed 3 Nov 2012
37. European Union (2001b) Communication from the Commission: Towards a strategic vision of life sciences and biotechnology: consultation document (COM(2001) 454 final). http://ec.europa.eu/biotechnology/docs/doc-en.pdf. Accessed 3 Nov 2012
38. European Union (2001c) Opinion on the state of the art concerning tissue engineering. Adopted by the scientific committee on medicinal products and medical devices on 1st October 2001 (Doc.SANCO/SCMPMD/2001/0006Final). http://ec.europa.eu/food/fs/sc/scmp/out37-en.pdf. Accessed 3 Nov 2012
39. European Union (2002a) Proposal for a directive of the European Parliament and of the Council on setting standards of quality and safety for the donation, procurement, testing, processing, storage, and distribution of human tissues and cells (COM(2002) 319 final). http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=COM:2002:0319:FIN:EN:PDF. Accessed 3 Nov 2012
40. European Union (2002b) European Commission: Communication from the Commission to the Council, the European Parliament, the economic and social committee and the committee of the regions: life sciences and biotechnology - a strategy for Europe (COM(2002) 27 final). http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=COM:2002:0027:FIN:EN:PDF. Accessed 3 Nov 2012
41. European Union (2002c) Communication from the Commission to the European Parliament pursuant to the second subparagraph of Article 251 (2) of the EC Treaty concerning the common position of the Council on the adoption of a Directive of the European Parliament and of the Council on setting standards of quality and safety for the donation, procurement, testing, processing, storage, and distribution of human tissues and cells (COD(2002)0128). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:52003SC0906:EN:HTML. Accessed 3 Nov 2012
42. European Union (2003a) Report on the proposal for a European Parliament and Council Directive on setting standards of quality and safety for the donation, procurement, testing, processing, storage, and distribution of human tissues and cells (Session document). http://www.europarl.europa.eu/sides/ getDoc.do?pubRef=-//EP//NONSGML+REPORT+A5-2003-0103+0+DOC+PDF+V0//EN. Accessed 3 Nov 2012
43. European Union (2003b) Amended Proposal for a European and Council Directive on Setting Standards of Quality and Safety for the Donation, Procurement, Testing, Processing, Storage, and Distribution of Human Tissues and Cells. http://europa.eu.int/eur-lex/en/com/pdf/2003/com2003-0340en01.pdf. Accessed 3 Nov 2012
44. European Union (2004) Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=OJ:L:2004:102:0048:0058:EN:PDF. Accessed 3 Nov 2012
45. European Union (2005a) Commission staff working document. Annex to the: proposal for a regulation on advanced therapy medicinal products impact assessment (SEC(2005) 1444). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do? uri=CELEX:52005SC1444:en:HTML. Accessed 3 Nov 2012
46. European Union (2005b) Action plan "Simplifying and improving the regulatory environment" (COM(2002) 278 final). http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do?uri=COM:2002:0278:FIN:EN:PDF. Accessed 3 Nov 2012
47. European Union (2005c) Communication from the Commission to the Council and the European Parliament: better regulation for growth and jobs in the European Union (COM(2005) 97 final). http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=COM:2005:0097:FIN:EN:PDF. Accessed 3 Nov 2012
48. European Union (2005d) European Commission (DG Enterprise & Industry): Human tissue engineering and beyond: proposal for a Community regulatory framework on advanced therapies. http://ec.europa.eu/health/files/ advtherapies/docs/implementationplan-2007-12-11-en.pdf. Accessed 3 Nov 2012
49. European Union (2006a) Commission Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells. http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=OJ:L:2006:038:0040:0052:EN:PDF. Accessed 3 Nov 2012
50. European Union (2006b) Commission Directive 2006/86/EC of 24 October 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells. http://eur-lex.europa.eu/LexUriServ/site/en/oj/2006/l-294/l- 29420061025en00320050.pdf. Accessed 3 Nov 2012
51. European Union (2006c) European transparency initiative (COM(2006) 194 final). http://europa.eu/documents/comm/green-papers/pdf/com2006-194-en.pdf. Accessed 3 Nov 2012
52. European Union (2007) Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137: en:PDF. Accessed 3 Nov 2012
53. European Union (2009) Commission Decision of 23 December 2009 on the renewal of the mandate of the European Group on Ethics in Science and New Technologies. http://ec.europa.eu/bepa/european-group-ethics/docs/decision-en. pdf. Accessed 3 Nov 2012
54. European Union (2010a) Interpretative document of the Commission's services: Placing on the market of medical devices. http://ec.europa.eu/health/ medical-devices/files/guide-stds-directives/placing-on-the-market-en.pdf. Accessed 3 Nov 2012
55. European Union (2010b) Report on the annual accounts of the European Medicines Agency for the financial year 2009, together with the Agency's replies. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2010:338: 0162:0167:EN:PDF. Accessed 3 Nov 2012
56. European Union (2010c) Commission decision of 3 August 2010 establishing guidelines concerning the conditions of inspections and control measures, and on the training and qualification of officials, in the field of human tissues and cells provided for in Directive 2004/23/EC of the European Parliament and of the Council (2010/453/EU). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri= OJ:L:2010:213:0048:0050:EN:PDF. Accessed 3 Nov 2012
57. European Union (2011) Resolution of the European Parliament of 10 May 2011 with observations forming an integral part of its decision on discharge in respect of the implementation of the budget of the European Medicines Agency for the financial year 2009. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri= OJ:L:2011:250:0174:0179:EN:PDF. Accessed 3 Nov 2012
58. European Union (2012) EU guidelines for good manufacturing practice for medicinal products for human and veterinary use. Annex 2: Manufacture of biological active substances and medicinal products for human use (revision 1). http://ec.europa.eu/health/files/eudralex/vol-4/vol4-an2-2012-06-en.pdf. Accessed 3 Nov 2013
59. FAMHP (2009) Ministerieel Besluit tot vaststelling van de prijs van menselijk lichaamsmateriaal. Staatsblad. http://staatsbladclip.zita.be/ staatsblad/wetten/2009/10/23/wet-2009018418.html. Accessed 3 Nov 2012
60. FAMHP (2011) The FAMPH moves beyond its Belgian borders - annual report 2010. http://www.fagg-afmps.be/nl/binaries/FAMPH-AnnualReport2010WEB-ENG-tcm290- 162579.pdf. Accessed 3 Nov 2012
61. FAMHP (2012a) Lijst van de erkende instellingen voor menselijk lichaamsmateriaal. Federal Agency for Medicines and Health Products. http://www.fagg-afmps.be/nl/binaries/LijstMLM121005-tcm290-28032.pdf. Accessed 3 Nov 2012
62. FAMHP (2012b) Menselijk lichaamsmateriaal (MLM): gebruik van greffes (2005-2011). Federal agency for medicines and health products. http://www.fagg-afmps.be/nl/binaries/Gebruikmenselijklichaamsmateriaal2005-2011- tcm290-73803.pdf. Accessed 3 Nov 2012
63. Faulkner A, Kent J, Geesink I, FitzPatrick D (2006) Purity and the dangers of regenerative medicine: regulatory innovation of human tissue-engineered technology. Soc Sci Med 63:2277-2288
64. Flear M (2009) The open method of coordination on health care after the Lisbon Strategy II: towards a neoliberal framing? Eur Integrat Online Pap (EIoP) 13(special issue 1):1-16. http://eiop.or.at/eiop/texte/2009-012a.htm. Accessed 2 Nov 2012
65. Fraunhofer-Gesellschaft (2012) Fraunhofer annual report 2011. http://www.fraunhofer.de/content/dam/zv/en/Publications/Annual-Report/ AnnualReport-2011.pdf. Accessed 3 Nov 2012
66. Friedman M (1970) The social responsibility of business is to increase its profits. The New York Times Magazine, 13 September. http://www.colorado.edu/ studentgroups/libertarians/issues/friedman-soc-resp-business.html. Accessed 3 Nov 2012
67. Geesink I (2005) EuropaBio industry hearing, tissue engineering and advanced therapies, report of the hearing. http://www.cardiff.ac.uk/socsi/ resources/PDF-10%20EuropaBio%20hearing%20report%2005.pdf. Accessed 3 Nov 2012
68. Hildebrandt M (2012) Advanced therapies in Europe: introductory remarks. Academic GMP - CONTRACT joint conference: the impact of EU legislation on therapeutic advance, Brussels, 11 October 2012
69. Hildebrandt M, Sethe S (2012) Caught in the gap: ATMP manufacture in academia. Telegraft 19:1-10. http://mediatum.ub.tum.de/doc/1100606/document.pdf. Accessed 2 Nov 2012
70. Hoeyer K (2010) An anthropological analysis of European Union (EU) health governance as biopolitics: the case of the EU tissues and cells directive. Soc Sci Med 70:1867-1873
71. Judge D, Earnshaw D (2011) "Relais actors" and codecision first reading agreements in the European Parliament: the case of the advanced therapies regulation. J Eur Pub Policy 18:53-71
72. Kent J (2005) Making connections - linking ethics and regulation in the social world of tissue engineering. Regulatory Affairs Focus, July 10
73. Kent A (2012) Patient's perspective. Academic GMP - CONTRACT joint conference: the impact of EU legislation on therapeutic advance, Brussels, 11 October 2012
74. Kent J, Faulkner A, Geesink I, FitzPatrick D (2006) Towards governance of human tissue engineered technologies in Europe: framing the case for a new regulatory regime. Technol Forecast Soc Chang 73:41-60
75. Kirkland M (2010) The precautionary principle: a double edged sword? Cell Tissue Bank 11:217-224
76. Klumb C (2011) Making cellular therapies available to patients: Possible regulatory pathways in Europe and Germany. Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels "Master of Drug Regulatory Affairs. "Rheinischen Friedrich-Wilhelms-Universität Bonn, Mathematisch- Naturwissenschaftlichen Fakultät. http://www.dgra.de/studiengang/pdf/ master-klumb-c.pdf. Accessed 3 Nov 2012
77. Le Grand J (2003) Motivation, agency and public policy: of knights and knaves, pawns and queens. Oxford University Press, Oxford
78. Loty B, Trindade H, Doyle P, Manyalich M, Abecassis M (2000) Working group's reports. Meeting on the Therapeutic Use of Human Organs and Tissues, Porto
79. Lowdell M (2012) Survey on the manufacture of ATMPs in academia. Academic GMP - CONTRACT joint conference: the impact of EU legislation on therapeutic advance, Brussels, 11 October 2012
80. Migliaccio G (2012) Infrastructures for translational research. Academic GMP - CONTRACT joint conference: the impact of EU legislation on therapeutic advance, Brussels, 11 October 2012
81. Mush G (2012) Advanced therapy medicinal products: clinical trial, hospital exemption, scientific advice, marketing authorisation. State of the Art FAMHP/EMA. BVWB Annual Spring Meeting, Brussels, 29 March 2012
82. No authors listed (2011) European Medicines Agency, CAT Secretariat & US Food and Drug Administration. Regen Med 6(Suppl 6):90-96
83. Office of Inspector General (2001) Informed consent in tissue donation - expectations and realities http://www.fda.gov/OHRMS/DOCKETS/ac/01/briefing/ 3736b2-02.pdf. Accessed 2 Nov 2012
84. Palucka K, Banchereau J (2011) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12:265-277
85. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9:203-214
86. Pincock S (2005) Biotech firms cheer EU proposal. The Scientist 2005, 23 November. http://www.the-scientist.com/?articles.view/articleNo/23512/title/ Biotech-firms-cheer-EU-proposal. Accessed 3 Nov 2012
87. Pirnay JP, Vanderkelen A, Zizi M, De Vos D, Rose T, Laire G, Ectors N, Verbeken G (2010) Human cells and tissues: the need for a global ethical framework. Bull World Health Organ 88:870-872
88. Pirnay JP, Vanderkelen A, Ectors N, Delloye C, Dufrane D, Baudoux E, Van Brussel M, Casaer MP, De Vos D, Draye JP, Rose T, Jennes S, Neirinckx P, Laire G, Zizi M, Verbeken G (2012a) Beware of the commercialization of human cells and tissues: situation in the European Union. Cell Tissue Bank 13:487-498
89. Pirnay JP, Verween G, Pascual B, Verbeken G, De Corte P, Rose T, Jennes S, Vanderkelen A, Marichal M, Heuninckx W, De Vos D (2012b) Evaluation of a microbiological screening and acceptance procedure for cryopreserved skin allografts based on 14 day cultures. Cell Tissue Bank 13:287-295
90. Risse M (2005) Should citizens of a welfare state be transformed into 'queens'? Econ Philos 21:291-303
91. Smith KE, Fooks G, Collin J, Weishaar H, Gilmore AB (2010a) Is the increasing policy use of impact assessment in Europe likely to undermine efforts to achieve healthy public policy? J Epidemiol Community Health 64:478-487
92. Smith KE, Fooks G, Collin J, Weishaar H, Mandal S, Gilmore AB (2010b) "Working the system" - British American Tobacco's influence on the European Union Treaty and its implications for policy: an analysis of internal tobacco industry documents. PLoS Med 7:e1000202
93. Steering Committee of the Istanbul Summit (2008) Organ trafficking and transplant tourism and commercialism: the declaration of Istanbul. Lancet 372:5-6
94. TiGenix (2011) Business and financial update for the first quarter of 2011. http://www.tigenix.com/public/uploads/pdf/en/f4ef44fe35c66c1.75077632- 2011-05-19-EN.pdf. Accessed 3 Nov 2012
95. Trommelmans L, Selling J, Dierickx K (2007a) Ethical issues in tissue engineering https://www.kuleuven.be/cbmer/viewpic.php?LAN=N&TABLE= DOCS&ID=446&PAGE=1. Accessed 2 Nov 2012
96. Trommelmans L, Selling J, Dierickx K (2007b) A critical assessment of the directive on tissue engineering of the European Union. Tissue Eng 13:667-672
97. Van Wilder P (2012) Advanced therapy medicinal products and exemptions to the regulation 1394/2007: how confident can we be? An exploratory analysis. Front Pharmacol 3:12
98. Vollebregt E (2011) European Commission consults on EU medical devices reimbursement harmonization. Medicaldeviceslegal.com. http:// medicaldeviceslegal.com/2011/03/31/european-commission-consults-on-eu-medical- devices-reimbursement-harmonisation/. Accessed 12 Nov 2012
99. Zandonella C (2003) The beat goes on. Nature 421:884-886